Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 6939.

https://doi.org/10.1182/blood-2023-178806

Published: 2023

Journal Articles

Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists

Elena Sabattini, Jadee Neff, Daisy Alapat, Thomas Tousseyn, Grzegorz Rymkiewicz, Henrique Moura de Paula, Kateřina Kamarádová, Santiago Montes Moreno, Stephen Lade

Blood (2022) 140 (Supplement 1): 13033–13034.

https://doi.org/10.1182/blood-2022-169712

Published: 2022

Journal Articles

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David A Westerman, Stephen Lade, David Ritchie, Rachel M Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen R Caldwell, Georgina L Ryland, Jing Xie, Huw Morgan, Michael Dickinson

Blood (2022) 140 (Supplement 1): 181–183.

https://doi.org/10.1182/blood-2022-160459

Published: 2022

Journal Articles

Defining double-hit lymphoma in the clinic

Piers Blombery, Stephen Lade

Blood (2021) 137 (16): 2132–2133.

https://doi.org/10.1182/blood.2020009465

Published: 2021

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Piers Blombery, MBBS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MD PhD, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, PhD FRACP, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 3999.

https://doi.org/10.1182/blood-2019-126396

Published: 2019

Journal Articles

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, MBBS, Jennifer Lickiss, MSc, BSc, Yamuna Kankanige, Satwica Yerneni, MS, John Markham, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Diego Villa, MD MPH, Graham W Slack, MD, Collin Chin, MBBS, Constantine S. Tam, MBBS (Hons), MD, Stephen Lade, MBBS, FRCPA, Niles Elizabeth Nelson, BSc, MBBS, Paul J Neeson, BSc, PhD, John F. Seymour, MBBS, PhD FRACP, Michael Dickinson, MBBS,FRACP,FRCPA, David Alan Westerman, MBBS, FRCPA, FRACP, Piers Blombery, MBBS

Blood (2019) 134 (Supplement_1): 4290.

https://doi.org/10.1182/blood-2019-127800

Published: 2019

Journal Articles

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, Mary Ann Anderson, MBBS, PhD FRACP, FRCPA, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Rodney J. Hicks, MB BS (Hons), MD FRACP, FAHMS, Besiat Birbirsa, B.N., Mathias Bressel, M.Sc, Juliana Di Iulio, PhD, David Alan Westerman, MBBS, FRCPA, FRACP, Stephen Lade, MBBS, FRCPA, Rishu Agarwal, Mark A. Dawson, PhD MBBS, Sarah-Jane Dawson, MD PhD, Rachel Koldej, David Ritchie, MD PhD, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 756.

https://doi.org/10.1182/blood-2019-126619

Published: 2019

Journal Articles

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome

Crystal Gao, Christopher McCormack, Carrie van der Weyden, Michelle S. Goh, Belinda A. Campbell, Robert Twigger, Odette Buelens, Simon J. Harrison, Christine Khoo, Stephen Lade, H. Miles Prince

Blood (2019) 134 (16): 1346–1350.

https://doi.org/10.1182/blood.2019000765

Published: 2019

Journal Articles

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Mary Ann Anderson, Constantine Tam, Thomas E. Lew, Surender Juneja, Manu Juneja, David Westerman, Meaghan Wall, Stephen Lade, Alexandra Gorelik, David C. S. Huang, John F. Seymour, Andrew W. Roberts

Blood (2017) 129 (25): 3362–3370.

https://doi.org/10.1182/blood-2017-01-763003

Published: 2017

Includes: Supplemental data

Journal Articles

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

Charlotte F. M. Hughes, Amit Khot, Christopher McCormack, Stephen Lade, David A. Westerman, Robert Twigger, Odette Buelens, Kate Newland, Constantine Tam, Michael Dickinson, Gail Ryan, David Ritchie, Colin Wood, H. Miles Prince

Blood (2015) 125 (1): 71–81.

https://doi.org/10.1182/blood-2014-07-588236

Published: 2015

Includes: Supplemental data

Journal Articles

Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation

Suzanne O. Arulogun, H. Miles Prince, Jonathan Ng, Stephen Lade, Gail F. Ryan, Odette Blewitt, Christopher McCormack

Blood (2008) 112 (8): 3082–3087.

https://doi.org/10.1182/blood-2008-05-154609

Published: 2008

NARROW

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Idiopathic Multicentric Castleman Disease Interactive Disease Awareness and Educational Tool for Pathologists

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Defining double-hit lymphoma in the clinic

Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with Sézary syndrome

Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax

Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy

Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only